Scientists at the 2026 ACTRIMS forum meet to assess current approaches and explore new directions for MS research and care.

Multiple sclerosis (MS) treatment could be on the brink of a significant breakthrough thanks to innovative research by Immunic Therapeutics. Speaking to Fierce Pharma, CEO Daniel Vitt shares insights ...

Neurologists have found in a recent study that common drugs to treat multiple sclerosis lead to modest health benefits but very high costs, according to a news release from Kirkland, Wash.-based ...

New MS treatments target myelin repair, neuroprotection, and CNS-resident immune cells, offering hope for progressive forms of the disease. Bruton tyrosine kinase inhibitors (BTKis) like tolebrutinib ...

BTK inhibitor implementation for MS treatment is explored. Ryan Haumschild, PharmD, MS, MBA: Now if we could, let’s discuss the emerging role of Bruton tyrosine kinase inhibitors [BTKis] in multiple ...

Smoldering-associated worsening (SAW) of multiple sclerosis (MS) deserves a broader, more comprehensive approach to diagnosis, treatment, and research that goes beyond neurologists’ understanding of ...

Scientists have used AI to identify two novel subtypes of multiple sclerosis (MS), which could offer new, targeted treatments for patients. MS affects around 2.8 million people across the world. It’s ...

"The observed differential effects of high-efficacy disease-modifying agents across sexes underscore the importance of sex-specific considerations in making treatment decisions to personalize care in ...

Kessler Foundation research scientist John DeLuca, PhD, has published a significant clinical article in Journal of Neurology, shedding light on the elusive nature of fatigue in multiple sclerosis (MS) ...

Improvements in safety, efficacy, and specificity have raised questions around the benefits and risks of switching treatments for this type of MS, especially from fingolimod to siponimod. There are ...